-
Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center
•
Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a cooperation memorandum of understanding (MoU) with Shanghai’s Class 3A Zhongshan Hospital, a major teaching hospital affiliated to China’s National Health Commission. The three entities will collaborate on clinical studies in cancer and other diseases, create…
-
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing group sales up 2% year-on-year (YOY) at constant exchange rates (CER) during the 9-month period to CHF 47.0 billion (USD 46.8 billion). The growth rates for Q1, Q2, and Q3 were +11%, +0%, and -6%…
-
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
•
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for its BAT1806, a biosimilar version of Roche Holding AG’s (SWX: ROG) Actemra/RoActemra (tocilizumab), has been accepted for review by the European Medicine Agency (EMA). This marks a significant step forward in the global development and…
-
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
•
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National Medical Products Administration (NMPA) for its generic version of Roche’s (SWX: ROG) Xofluza (baloxavir marboxil) on October 11, 2022. This approval marks a significant development in the availability of generic influenza treatments in China. However,…
-
Roche’s Subcutaneous Herceptin Approved in China for HER2-Positive Breast Cancer
•
Swiss pharmaceutical giant Roche’s (SWX: ROG) Herceptin (trastuzumab, subcutaneous injection) has been approved in China for the treatment of early and metastatic HER2-positive breast cancer in combination with chemotherapy. This approval marks a significant advancement in the treatment options available for patients with HER2-positive breast cancer, offering a more convenient…
-
Roche Boosts China Investment with Additional RMB 250 Million
•
Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million (USD 35.1 million) in China, underscoring its commitment to the market despite challenges posed by the COVID-19 pandemic. The announcement was made during the 34th International Business Leaders’ Advisory Council for the Mayor of Shanghai.…
